TB-500 Dosage: Loading, Maintenance and Cycle Breakdown

What Is The Right TB-500 Dosage?

The standard TB-500 dosage is 2-2.5mg injected subcutaneously (under the skin), twice weekly for 4-6 weeks. That is the loading phase. Maintenance drops to 2-2.5mg once weekly. Inject into your abdomen or near the injury. A full cycle caps at 8-12 weeks, then you take a minimum 4-week break.

This dosage turns up across research logs and coach-supervised programmes. It is not one forum thread you stumbled on. It is the number that has held steady for years. It sits in a practical margin: enough peptide to matter, without paying for exposure that buys you nothing.

Run it like this. Reconstitute the vial with bacteriostatic water. Roughly 2-3ml is standard for a 5mg vial, which gives you 2-2.5mg per 1ml draw. Draw the dose into an insulin syringe. Inject subcutaneously, rotating between the lower abdomen, the thigh, or the tissue around the injury. Twice weekly means about 72 hours apart, so Monday and Thursday.

This content is for educational purposes only. TB-500 is intended for research use. Nothing here is medical advice, and any decision about a peptide protocol should involve a qualified clinician.

What Does The TB-500 And BPC-157 Dosage Chart Look Like?

The whole cycle on one page.

The loading phase builds peptide presence around the injury while your body works through the early stages of repair. Six weeks is the usual ceiling. Most soft-tissue injuries move through their acute repair window inside that time. If you see no functional improvement by week 6, do not keep adjusting the protocol. Look again at the diagnosis or your rehab loading instead.

Maintenance at half the frequency keeps peptide available without extra total exposure. When the cycle closes, stop cleanly rather than tapering. There is no evidence requiring a slow wind-down. The break also tells you whether the gains held without the peptide in your system.

What Is The BPC-157 + TB-500 Blend Dosage Per Day?

In the common pairing, BPC-157 runs at 250-500mcg daily, split into two doses under the skin. TB-500 does not run daily. It runs at 2-2.5mg twice a week during loading, then once a week after that. So only one of the two is a daily injection. This is the most common point of confusion with blends.

The logic is mechanistic, not marketing. TB-500 acts on actin (a protein your cells use to move and rebuild) throughout your whole body. BPC-157 works more locally, especially around tendon-to-bone junctions and your gut lining. Running them in the same window covers both angles of a soft-tissue injury instead of betting on one. The BPC-157 and TB-500 stack breakdown walks through timing and site rotation in more depth.

You might add GHK-Cu too, to help skin and connective tissue. It usually runs on its own schedule, separate from your TB-500 injection days. The GHK-Cu recovery guide covers its dosing in full.

Is There A BPC-157 TB-500 Blend Dosage Calculator?

You might expect a TB-500 dosage calculator here, or one for the BPC-157 blend. There isn't one, and there's a reason.

A blend vial does not carry one single dose. It holds two compounds mixed in a ratio the manufacturer chose, and that ratio changes between sellers. A vial labelled only "10mg blend" does not tell you how much of each compound is inside. Without that split, no calculator, including ours, can give you a correct dose. It would just be guessing with a nice interface.

So do it by hand. Read the label for the milligrams of each compound, not the combined total. Divide each by the millilitres of bacteriostatic water you added. That gives you milligrams per millilitre for each compound. Then work out which compound decides your draw. In this pairing the two need different frequencies. So one of them will always be slightly off, unless the blend was mixed for the ratio you actually want.

That is the real answer to the calculator question. A blend is a convenience, and it costs you dosing precision. Separate vials let you run each compound at its own dose and its own frequency. If your label does not state the split, you cannot dose it accurately, and no arithmetic fixes that.

What Is The BPC-157 TB-500 Blend Reconstitution Dosage?

Your mixing decides your dose.

The peptide arrives as a freeze-dried powder. The bacteriostatic water you add sets the concentration, and nothing else does. Add 2ml to a 5mg vial and each millilitre holds 2.5mg. Add 3ml to the same vial and each millilitre holds about 1.67mg. The powder did not change. Your draw did.

This is where blends go wrong most often. You reconstitute to a round number for one compound, then draw as though it applies to both. The reconstitution walkthrough covers water volume, storage and stability windows. That way, the 2-2.5mg you think you're drawing is what actually ends up in the syringe.

What Is The BPC-157 And TB-500 Dosage For Injury?

Placement changes with the injury, not the dose.

Injecting subcutaneously (under the skin) into your abdomen or thigh spreads the peptide through your whole body. It is the simplest, most repeatable route, and the default choice for general recovery or a broader stack. Local injection means placing the needle near the injured joint or tendon instead. You'll use this if you're targeting one well-defined problem, such as a shoulder or knee. The theory is that proximity raises local concentration faster than circulation would.

Keep the volume small, under 0.5ml per site. Do not inject into the joint capsule or the tendon itself. That needs a different technique, with different sterile handling. It is not something you do yourself. No published human trial has compared injecting locally versus systemically for TB-500. So the choice comes down to injury location and personal preference, not settled evidence.

If the injury is structural, not just a soft-tissue strain, these numbers may not apply. Check the disc-specific article or the meniscus stack without surgery guide first.

What Does The Human Safety Data Show About TB-500 Dosage?

A first-in-human trial of recombinant thymosin beta-4 tested 0.05 to 25 micrograms per kilogram intravenously. It found no dose-limiting toxicities and no serious adverse events. A separate synthetic thymosin beta-4 trial ran 42-1260mg over 14 days with the same safety profile.

These are the closest human data points for the parent peptide TB-500 comes from. The first-in-human study ran single ascending doses up to 25mcg/kg, and daily dosing up to 5mcg/kg for 10 days. Adverse events were mild to moderate, and no accumulation was detected across repeated doses (Wang et al. 2021).

That fits the binding chemistry. Thymosin beta-4 binds G-actin in a fast, reversible 1:1 complex, with a dissociation constant around 2 micromolar. In plain terms, it does not build up in tissue. It cycles on and off actin in seconds (Jean et al. 1994).

The higher-dose trial used 42mg up to 1260mg over 14 consecutive days, again with no dose-limiting toxicity. Those numbers dwarf a 2-2.5mg subcutaneous protocol. That is why the standard dose sits well inside a wide safety margin rather than near any observed ceiling. None of it is an approved indication, and none of it is a green light to self-administer without oversight.

Can You Run TB-500 Dosage Beyond 12 Weeks?

There is no published long-term human safety data for TB-500 beyond a matter of weeks. The practical limit you'll see used is 12 weeks per cycle, with a mandatory break. Peptides that promote blood vessel growth carry a theoretical tumour-promotion concern. That concern has not been confirmed, or ruled out, over long durations.

Thymosin beta-4 promotes cell migration, angiogenesis and reduced apoptosis. Angiogenesis is new blood vessel growth. Apoptosis is programmed cell death. Those are the same mechanisms that make it useful for repair. Vessel-sprouting assays show its actin-binding motif driving near-maximal angiogenic activity at around 50 nanomolar. That is well below what a milligram-scale weekly dose implies (Philp et al. 2003). Separate work in fibrotic tissue models shows the same pathway suppressing programmed cell death (Yuan et al. 2017).

That is exactly why using it for a long time without a break raises concern. Any compound that strongly boosts new blood vessels and lowers cell death needs long-term human data. That data does not exist yet. So the 8-12 week cycle-and-break plan is not based on a trial that compared week 16 to week 8. It is a cautious limit that keeps total exposure low while research stays limited. If you're dealing with an ongoing, chronic problem rather than one injury, this changes slightly. Cycle with real breaks, and check in with a doctor. That is the safer approach for you.

What Does TB-500 Tendon Healing Evidence Actually Show?

Thinner than the protocols suggest.

No completed human trial has tested TB-500 on a tendon. Not an Achilles, not anything else. TB-500 is a synthetic fragment of thymosin beta-4. The parent molecule drives actin sequestering and cell migration across many tissue types (Goldstein et al. 2005). That is the mechanism the protocol above extrapolates from. It is not tendon-specific.

The nearest musculoskeletal work is a rodent (rat) knee ligament model. Localised thymosin beta-4 produced better organised collagen bundles. Fibril diameter at 4 weeks was larger than in untreated controls (Xu et al. 2013). A rat knee ligament is not a human Achilles. It is the closest thing on the record.

A 2026 scoping review said it plainly. Direct musculoskeletal evidence for TB-500, tendon included, is sparse next to the eye and skin wound data (McGuire et al. 2026). Treat any healing percentage claimed for a tendon as fiction. That number does not exist in the data.

BPC-157 is the better-evidenced half of the pair here. In a rodent (rat) Achilles detachment model it improved tendon-to-bone healing. It also increased type I collagen organisation against controls (Krivic et al. 2006). Separate work found it raised growth hormone receptor expression in tendon fibroblasts (Chang et al. 2010). Our BPC-157 tendon repair article covers that evidence in full.

If your injury is an Achilles specifically, here is the practical read. A protocol without a loading programme treats only half the problem. Isometrics, heel drops and a graded return to sprint work do the rest. Peptide input without mechanical input rarely holds once your training volume climbs back.

How Do You Verify TB-500 Quality Before You Start?

None of the dosing above matters if the vial does not hold what the label claims. Third-party testing failures are common across the unregulated research peptide market, and TB-500 is not exempt. Check how to verify a peptide is real and review independent purity testing standards, so the dose you calculate reflects what is in the syringe. Our recommended sources page lists vendors providing certificates of analysis for every batch.

Who Actually Runs This TB-500 Dosage Protocol?

This protocol isn't for chasing aesthetics. You're picking it up for one of three reasons. Maybe you're rebuilding a shoulder after a layoff. Maybe you're managing a tendon problem that rest alone will not fix. Or maybe you're working through the joint wear that comes with getting back into serious training. The protocol above is built for that: a defined injury, a defined cycle, and a defined stop point. It is not meant for indefinite use as a wellness habit.

Frequently Asked Questions About TB-500 Dosage

Here are the six questions you're most likely to have about TB-500 dosage.